Biosimilars are a rapidly expanding class of medicines that can be substituted for expensive biologic drugs in treating many serious and chronic conditions.
They are forecasted to save billions in healthcare costs for patients and the state, just as generics have compared to branded drugs.
Legislation is being introduced in SC in 2017 to increase access to cutting-edge biosimilar medicines, while ensuring patient safety and protecting prescribers.
Learn more about this legislation and why it’s vitally important to patients across our state. Also, come engage with legislators as well as national and state industry leaders about the future of biotech in SC.
SCBIOSuite 304, Legacy Square340 Rocky Slope RoadGreenville, SC 29607864-313-2277Copyright © 2014 SCBIO ®. All rights reserved.